2419 related articles for article (PubMed ID: 18922242)
1. [Predictors of prophylactic response to lithium].
Rohayem J; Baylé JF; Richa S
Encephale; 2008 Sep; 34(4):394-9. PubMed ID: 18922242
[TBL] [Abstract][Full Text] [Related]
2. Biological predictors of lithium response in bipolar disorder.
Ikeda A; Kato T
Psychiatry Clin Neurosci; 2003 Jun; 57(3):243-50. PubMed ID: 12753562
[TBL] [Abstract][Full Text] [Related]
3. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
Auxéméry Y
Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
[TBL] [Abstract][Full Text] [Related]
4. Rational polypharmacy in the bipolar affective disorders.
Post RM; Ketter TA; Pazzaglia PJ; Denicoff K; George MS; Callahan A; Leverich G; Frye M
Epilepsy Res Suppl; 1996; 11():153-80. PubMed ID: 9294735
[TBL] [Abstract][Full Text] [Related]
5. Further evidence for a possible association between serotonin transporter gene and lithium prophylaxis in mood disorders.
Serretti A; Malitas PN; Mandelli L; Lorenzi C; Ploia C; Alevizos B; Nikolaou C; Boufidou F; Christodoulou GN; Smeraldi E
Pharmacogenomics J; 2004; 4(4):267-73. PubMed ID: 15111989
[TBL] [Abstract][Full Text] [Related]
6. [Long-term lithium prophylaxis in the bipolar affective disorder].
Suwalska A; Chłopocka-Woźniak M; Rybakowski J
Psychiatr Pol; 2002; 36(6 Suppl):63-9. PubMed ID: 12647423
[TBL] [Abstract][Full Text] [Related]
7. [Prediction of treatment response in acute mania: controlled clinical trials with divalproex].
Swann AC
Encephale; 2001; 27(3):277-9. PubMed ID: 11488258
[TBL] [Abstract][Full Text] [Related]
8. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder.
McQuillin A; Rizig M; Gurling HM
Pharmacogenet Genomics; 2007 Aug; 17(8):605-17. PubMed ID: 17622937
[TBL] [Abstract][Full Text] [Related]
9. Clinical features, response to treatment and functional outcome of bipolar disorder patients with and without co-occurring substance use disorder: 1-year follow-up.
Mazza M; Mandelli L; Di Nicola M; Harnic D; Catalano V; Tedeschi D; Martinotti G; Colombo R; Bria P; Serretti A; Janiri L
J Affect Disord; 2009 May; 115(1-2):27-35. PubMed ID: 18845344
[TBL] [Abstract][Full Text] [Related]
10. Is the polarity of relapse/recurrence in bipolar-I disorder patients related to serum lithium levels? Results from an empirical study.
Severus WE; Kleindienst N; Evoniuk G; Bowden C; Möller HJ; Bohus M; Frangou S; Greil W; Calabrese JR
J Affect Disord; 2009 Jun; 115(3):466-70. PubMed ID: 19019453
[TBL] [Abstract][Full Text] [Related]
11. Long-term pharmacological treatment of bipolar disorders.
Rybakowski J
Neuro Endocrinol Lett; 2007 Feb; 28 Suppl 1():71-93. PubMed ID: 17262006
[TBL] [Abstract][Full Text] [Related]
12. Loudness dependence of primary auditory-cortex-evoked activity as predictor of therapeutic outcome to prophylactic lithium treatment in affective disorders--a retrospective study.
Juckel G; Mavrogiorgou P; Bredemeier S; Gallinat J; Frodl T; Schulz C; Möller HJ; Hegerl U
Pharmacopsychiatry; 2004 Mar; 37(2):46-51. PubMed ID: 15048610
[TBL] [Abstract][Full Text] [Related]
13. Anticonvulsants in bipolar disorder.
Singh V; Muzina DJ; Calabrese JR
Psychiatr Clin North Am; 2005 Jun; 28(2):301-23. PubMed ID: 15826734
[TBL] [Abstract][Full Text] [Related]
14. Lithium in the long-term treatment of bipolar disorders.
Kleindienst N; Greil W
Eur Arch Psychiatry Clin Neurosci; 2003 Jun; 253(3):120-5. PubMed ID: 12904975
[TBL] [Abstract][Full Text] [Related]
15. [Predictors of response to phase prophylactics (mood stabilizers) in bipolar affective disorders].
Walden J; Normann C; Langosch J; Grunze H
Fortschr Neurol Psychiatr; 1999 Feb; 67(2):75-80. PubMed ID: 10093780
[TBL] [Abstract][Full Text] [Related]
16. Pharmacogenetics of lithium response in bipolar disorder.
Alda M
J Psychiatry Neurosci; 1999 Mar; 24(2):154-8. PubMed ID: 10212559
[TBL] [Abstract][Full Text] [Related]
17. Factors associated with response to lithium prophylaxis in DSM III major depression and bipolar disorder.
Maj M; Arena F; Lovero N; Pirozzi R; Kemali D
Pharmacopsychiatry; 1985 Sep; 18(5):309-13. PubMed ID: 3931108
[TBL] [Abstract][Full Text] [Related]
18. Prophylaxis of schizoaffective disorder with lithium or carbamazepine: outcome after long-term follow-up.
Baethge C; Gruschka P; Berghöfer A; Bauer M; Müller-Oerlinghausen B; Bschor T; Smolka MN
J Affect Disord; 2004 Apr; 79(1-3):43-50. PubMed ID: 15023479
[TBL] [Abstract][Full Text] [Related]
19. [Child and adolescent bipolar disorder].
Aichhorn W; Stuppäck C; Kralovec K; Yazdi K; Aichhorn M; Hausmann A
Neuropsychiatr; 2007; 21(2):84-92. PubMed ID: 17640494
[TBL] [Abstract][Full Text] [Related]
20. Prediction of lithium response in affective disorders.
Ananth J; Pecknold JC
J Clin Psychiatry; 1978 Feb; 39(2):95-100. PubMed ID: 344305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
